Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

Waiver Agreement

As previously disclosed, on July 21, 2025, Datavault AI Inc., a Delaware corporation (the "Company"), entered into an agreement (the "Waiver Agreement") with the purchasers (the "Purchasers") party to that certain securities purchase agreement, dated March 31, 2025, with purchasers thereto (the "March 2025 Purchase Agreement"), pursuant to which the Purchasers waived the provisions relating to variable rate transactions contained in the March 2025 Purchase Agreement for a period of 60 days and the provisions relating to participation rights contained in the March 2025 Purchase Agreement, and the Company agreed that until the earlier to occur of (a) the end of the 60-day period beginning on the trading date after the date of the Waiver Agreement, and (b) when no Purchaser holds any of the Notes (as defined in the March 2025 Purchase Agreement), the Corporation will not sell shares of common stock of the Company, par value $0.0001 per share (the "Common Stock"), pursuant to that certain sales agreement, dated July 21, 2025, by and between the Company and Maxim Group LLC, (a)(i) on any trading day in an amount exceeding 10% of the trading volume of the shares of Common Stock on such trading day during regular trading hours, or (ii) outside of regular trading hours, (b) at a per share price below $1.10, or (c) in an aggregate amount exceeding $25,000,000.

In consideration of the waiver granted by the Purchasers under the Waiver Agreement, the Company agreed to issue an aggregate of 5,000,000 shares of Common Stock to the Purchasers on the date the Company receives stockholder approval for such issuance under applicable stock exchange rules.

Written Consent

On August 27, 2025, the holders of an aggregate of 50,365,422 shares of Common Stock, representing approximately 52% of the overall voting power of the Company, executed a written consent (the "Written Consent") in lieu of a meeting to approve the issuance of shares of Common Stock pursuant to the Waiver Agreement in the aggregate maximum amount of 5,000,000 for purposes of complying with Nasdaq Listing Rule 5635(d), to the extent required.

Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), an information statement on Schedule 14C (the "Information Statement") describing the actions approved in the Written Consent will be filed with the SEC and mailed to the Company's stockholders. None of the actions approved in the Written Consent may become effective earlier than 20 calendar days following the mailing of the Information Statement.